Cabaletta Bio Registered Logo.png
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors
June 28, 2021 08:00 ET | Cabaletta Bio
Dr. Brun’s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta’s rapidly emerging pipeline PHILADELPHIA, June 28, 2021 ...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 27, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
May 03, 2021 07:05 ET | Cabaletta Bio
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
May 03, 2021 07:00 ET | Cabaletta Bio
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – Second dose cohort to be initiated after the third patient...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
April 07, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
logo.png
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
March 16, 2021 07:30 ET | Cabaletta Bio
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
logo.png
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 23, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Participate in Upcoming January Investor Conferences
January 04, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris
December 08, 2020 16:30 ET | Cabaletta Bio
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune...